Should patient compliance be included in pharmaco-economic evaluations? An explorative analysis in Germany

被引：0

作者：

Schalk, Katharina ^{[1
]}

Thanner, Mirjam ^{[1
]}

Loss, Julika ^{[1
]}

Jaeger, Anne ^{[1
]}

Nagel, Eckhard ^{[1
]}

机构：

[1] Univ Bayreuth, Inst Hlth Care Sci & Management Med, Bayreuth, Germany

来源：

PHARMACY WORLD & SCIENCE | 2009年 / 31卷 / 02期

关键词：

Compliance; Pharmaco-economic evaluation; Sensitivity analysis;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：322 / 323

页数：2

共 50 条

[31] Unrelated Medical Costs in Life-Years Gained Should They be Included in Economic Evaluations of Healthcare Interventions?
Rappange, David R.
van Baal, Pieter H. M.
van Exel, N. Job A.
Feenstra, Talitha L.
Rutten, Frans F. H.
Brouwer, Werner B. F.
PHARMACOECONOMICS, 2008, 26 (10) : 815 - 830
[32] Pharmaco-economic analysis of the use of the genomic test Mammaprint® for patients with breast cancer treated in a private health institution in Brazil
Mansani, Fabio Postiglione
Koppen, Morgana
CANCER RESEARCH, 2020, 80 (04)
[33] Clinical efficacy and pharmaco-economic analysis of xiaozhong zhitong decoction on preventing deep venous thrombosis in major orthopaedic operation
Guan, Xiliang
Li, Bin
Wang, Yingzhen
PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 31 (05) : 2291 - 2294
[34] Economic Evaluation Should Patient Compliance be increased through financial Incentives?
Thiem, Helena
GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2019, 24 (06): : 268 - +
[35] Analysis of drug pricing drivers under South Korea's pharmaco-economic evaluation exemption policy (2015-2022)
Yu, Seung Rae
Lee, Jong Hyuk
FRONTIERS IN PHARMACOLOGY, 2025, 15
[36] First interim results on treatment satisfaction and pharmaco-economic data comparing Fingolimod and first-line therapies in multiple sclerosis patients in Germany (PANGAEA and PEARL)
Ortler, Sonja
Ziemssen, Tjalf
Antonius, van Lokven
Meergans, Matthias
JOURNAL OF NEUROIMMUNOLOGY, 2012, 253 (1-2) : 31 - 32
[37] Pharmaco-economic analysis of valsartan/hydrochlorothiazide (HCTZ) versus candesartan/HCTZ and versus telmisartan/HCTZ in the treatment of systemic arterial hypertension in Mexico
Carlos, FDJ
Guzmán, JA
D'ector, DM
Castillejos, C
Fon, F
VALUE IN HEALTH, 2005, 8 (06) : A106 - A107
[38] COST-EFFECTIVENESS OF ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: A PHARMACO-ECONOMIC ANALYSIS OF THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS) IN THE BELGIAN POPULATION
Marbaix, S.
Vandenberghe, H.
Van Gaal, L.
VALUE IN HEALTH, 2008, 11 (06) : A343 - A343
[39] Interim Results of the PANGAEA and PEARL Studies, Comparing Treatment Satisfaction and Pharmaco-Economic Data of Fingolimod (Gilenya®) and First-Line Therapies in Multiple Sclerosis Patients in Germany
Ziemssen, Tjalf
Vollmar, Patrick
Meergans, Matthias
Tracik, Ferenc Mark
Lorente, Maria Diaz
Neidhardt, Katja
van Lokven, Tom
NEUROLOGY, 2013, 80
[40] Cost-effectiveness analysis and time-trade-off for natalizumab in recurrent-remitting multiple sclerosis in Brazil: a pharmaco-economic evaluation
Tilbery, C.
Gabbai, A.
Alvarenga, R.
Leon, S.
Ferreira, M. Brito
Callegaro, D.
Saraiva, S.
Pericles, C.
MULTIPLE SCLEROSIS, 2009, 15 (09): : S57 - S57

← 1 2 3 4 5 →